Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406910 | 1.00 | PRMT6 (0.45) | PRMT6SLC6A9KCNH2HDAC1HDAC2 | |
| SCHEMBL799291 | 0.80 | PRMT6 (0.50) | PRMT6SLC6A9KCNH2HDAC1HDAC2 | |
| SCHEMBL6407493 | 0.78 | RXRA (0.45) | — | |
| SCHEMBL8371383 | 0.78 | RXRA (0.45) | — | |
| SCHEMBL8371385 | 0.78 | RXRA (0.45) | — | |
| SCHEMBL27222055 | 0.77 | PRMT6 (0.47) | PRMT6SLC6A9KCNH2HDAC1HDAC2 | |
| SCHEMBL27231700 | 0.77 | PRMT6 (0.47) | PRMT6SLC6A9KCNH2HDAC1HDAC2 | |
| SCHEMBL31261569 | 0.75 | PTGS1 (0.49) | SLC6A9HDAC1HDAC2HDAC3CYP3A4 | |
| SCHEMBL13140935 | 0.74 | PRMT6 (0.49) | PRMT6SLC6A9KCNH2HDAC2LTA4H | |
| SCHEMBL38650787 | 0.74 | KAT6A (0.47) | PRMT6SLC6A9KCNH2HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| WO-2003013518-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | PRMT6 4227/4885SLC6A9 4544/4885KCNH2 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.